FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 872 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 Breathing for Stress Reduction March 10, 2021 Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... February 11, 2020 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 Load more HOT NEWS Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors The Power of Fruits and Vegetables Moving target – retrotransposable elements and cancer Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:...
